Related Experiment Videos
Is cardiovascular disease preventable by vaccination?
1National Public Health Institute, Helsinki, Finland. pirjo.makela@ktl.fi
Insights
Developing a Chlamydia pneumoniae vaccine for cardiovascular disease prevention is challenging but ongoing. Research confirms the bacteria
Area of Science:
- Cardiovascular Science
- Infectious Disease Immunology
Background:
- Chlamydia pneumoniae infection is an independent risk factor for cardiovascular disease, including acute myocardial infarction.
- Epidemiological data and detection of C. pneumoniae in vascular lesions support its role in atherosclerosis.
- Antimicrobial drug trials suggest a pathogenic relationship between C. pneumoniae and cardiovascular disease.
Purpose of the Study:
- To evaluate the potential of vaccination for preventing atherosclerotic cardiovascular disease.
- To discuss the challenges and ongoing developments in creating a C. pneumoniae vaccine.
Main Methods:
- Review of epidemiological studies linking C. pneumoniae to cardiovascular disease.
- Analysis of findings from antimicrobial intervention trials.
- Consideration of immunological challenges and biotechnological advancements for vaccine development.
Main Results:
- Accumulated data confirm the association between C. pneumoniae and cardiovascular disease.
- The development of a C. pneumoniae vaccine is ongoing but faces significant immunological hurdles.
- Biotechnological advances, such as genome sequencing, offer tools for vaccine design.
Conclusions:
- Further confirmation of C. pneumoniae's role is needed before vaccine deployment.
- Vaccine development requires overcoming challenges related to intracellular bacteria and T-cell stimulation.
- Extensive clinical trials will be necessary to ensure the safety of a novel C. pneumoniae vaccine.
Abstract:
The possibility of using vaccination as a tool in the prevention of atherosclerotic disease was opened by the findings that infection with Chlamydia pneumoniae was an independent risk factor for cardiovascular disease, including acute myocardial infarction. Since this finding, data have accumulated confirming the initial epidemiological association and demonstrating the presence of C. pneumoniae and/or its components in vascular lesions. Recent intervention trials with antimicrobial drugs have furthermore suggested a pathogenetic relationship. The role of C. pneumoniae needs, however, to be further confirmed before deciding on the use of a possible vaccine. At present, a vaccine for C. pneumoniae is not available but development is ongoing. The task is far from easy: the intracellular bacteria cannot be reached by antibodies, and the stimulation of CD8+ T cells required for protection is difficult with a nonliving vaccine. On the other hand, recent advances in biotechnology, including the sequence of the full genome of C. pneumoniae, provide unique tools for the work. With enough interest in the development of a C. pneumoniae vaccine the first clinical trials could be expected in several years' time. They will, however, have to be extensive in order to ascertain the safety of such a new type of vaccine intended for use in populations in which many have already been infected with the bacteria and many are chronic carriers. Who should be vaccinated is a question to be considered at that point.